Neuropeptides in learning and memory processes

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 83-90

  De Wied, D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

learning; memory; neuropeptide

Indexed keywords

NEUROPEPTIDE;

AMNESIA; ANIMAL; CONFERENCE PAPER; HUMAN; LEARNING; MEMORY; NONHUMAN; PRIORITY JOURNAL;

EID: 0031081163     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86050-0     Document Type: Conference Paper

References (76)

1. 5 receptors, Eur. J. Pharmacol. (Mol. Pharmacol.), 269 (1994) 331-337.
2. [2] Bannon, M.J., Haverstick, D.M., Shibata, K. and Poosch, M.S., Preprotachykinin gene expression in the forebrain; regulation by dopamine, Ann. New York Acad. Sci., 632 (1991) 31-37.
3. 3H)Vasopressin binding to rat hippocampal synaptic plasma membrane, FEBS Lett., 162 (1983) 400-405.
4. [4] Bidzseranova, A., Penke, B., Toth, G. and Telegdy, G., The effects of atrial natriuretic peptide on electroconvulsive shock-induced amnesia in rats. Transmitter-mediated action, Neuropeptides, 19 (1991) 103-106.
5. [5] Biegon, A., Terlou, M., Voorhuis, Th.D. and De Kloet, E.R., Arginine-vasopressin binding sites in rat brain; a quantitative autoradiographic study, Neurosci. Lett., 44 (1984) 229-234.
6. [6] Birnbaumer, M., Seibold, A., Gilbert, S., Ishido, M., Barbéris, C., Antaramian, A., Brabet, P. and Rosenthal, W., Molecular cloning of the receptor for human antidiuretic hormone, Nature, 357 (1992) 333-335.
7. [7] Bohus, B. and De Wied, D., Pituitary-adrenal system hormones and adaptive behaviour. In: I.C. Jones and I.W. Henderson (Eds.), General, Comparative and Clinical Endocrinology of the Adrenal Cortex, Academic Press, London, 1980, pp. 265-347.
8. [8] Bohus, B., Kovács, G.L., Greven, H.M. and De Wied, D., Oxytocin, vasopressin and memory: opposite effects on consolidation and memory processes, Brain Res., 157 (1978) 414-417.
9. [9] Bohus, B., Conti, L., Kovács, G.L. and Versteeg, D.H.G., Modulation of memory processes by neuropeptides (interaction with transmitter systems. In: C.A. Marsan and H. Matthies (Eds.), Neuronal Plasticity and Memory Formation, Raven Press, New York, 1982, pp. 75-87.
10. [10] Born, J., Fehm, H.L. and Voigt, K.H., ACTH and attention in humans: a review, Neuropsychobiology, 15 (1986) 165-186.
11. 8)-Vasopressin and Cognitive Processes in Healthy Subject, Thesis, Utrecht, 1991.
12. [12] Buijs, R.M., De Vries, G.J., Van Leeuwen, F.W. and Swaab, D.F., Vasopressin and oxytocin (distribution and putative functions in the brain), Prog. Brain Res., 60 (1983) 115-122.
13. [13] Burbach, J.P.H., Action of proteolytic enzymes on lipotropins and endorphins (biosynthesis, biotransformation and fate. In: D. De Wied, W.H. Gispen and Tj.B. Van Wimersma Greidanus (Eds.), Neuropeptides and Behaviour. CNS Effects of ACTH, MSH and Opioid Peptides, Pergamon Press, Oxford, 1986, pp. 43-76.
14. [14] Burbach, J.P.H., Kovács, G.L., De Wied, D., Van Nispen, J.W. and Greven, H.M., A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide, Science, 221 (1983) 1310-1312.
15. [15] Chen, C., Diaz Brinton, R., Shors, T.J. and Thompson, R.F., Vasopressin induction of long-lasting potentiation of synaptic transmission in the dentate gyrus, Hippocampus, 3 (1993) 193-204.
16. [16] Colombo, G., Hansen, C., Hoffman, P.L. and Grant, K.A., Decreased performance in a delayed alternation task by rats genetically deficient in vasopressin, Physiol. Behav., 52 (1992) 827-830.
17. [17] Dantzer, R. and Bluthé, R.M., Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate social recognition in rat, Brain Res., 572 (1992) 261-264.
18. [18] De Kloet, E.R., Rotteveel, F., Voorhuis, Th.D. and Terlou, M., Topography of binding sites for neurohypophyseal hormones in rat brain, Eur. J. Pharmacol., 110 (1985) 113-119.
19. [19] De Noble, V.J., De Noble, K.F., Spencer, K.R., Chiu, A.T., Wong, P.C. and Timmerman, P.B.M.W.M., Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor; effect on renin-induced deficit of passive avoidance response in rats, Brain Res., 561 (1991) 230-235.
20. [20] De Wied, D., Effects of peptide hormones on behavior, Front. Neuroendocrinol., 1 (1969) 97-140.
21. [21] De Wied, D., Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments, Life Sci., 19 (1976) 685-690.
22. [22] De Wied, D., The neuropeptide concept, Prog. Brain. Res., 72 (1987) 93-108.
23. [23] De Wied, D. and Jolles, J., Neuropeptides derived from pro-opio-cortin (behavioral, physiological, and neurochemical effects, Physiol. Rev., 62 (1982) 976-1059.
24. [24] De Wied, D., Gaffori, O., Burbach, P., Kovács, G.L. and Van Ree, J.M., Structure activity relationship studies with C-terminal fragments of vasopressin and oxytocin on avoidance behaviors of rats, J. Pharmacol. Exp. Ther., 241 (1987) 268-274.
25. [25] De Wied, D., Elands, J. and Kovács, G., Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior; mediation by a cerebral neurohypophyseal hormone receptor? Proc. Natl. Acad. Sci. USA, 88 (1991) 1494-1498.
26. [26] De Wied, D., Diamant, M. and Fodor, M., Central nervous system effects of the neurohypophyseal hormones and related peptides, Front. Neuroendocrinol., 14 (1993) 251-302.
27. [27] Dekker, A., Gispen, W.H. and De Wied, D., Axonal regeneration, growth factors and neuropeptides, Life Sci., 41 (1987) 1667-1678.
28. [28] Drago F., Behavioral effects of prolactin. In: D. Ganten and D. Pfaff (Eds.), Current Topics in Neuroendocrinology, Vol. 10, Springer, Berlin, 1990, pp. 263-289.
29. [29] Dunn, A.J. and Berridge, C.W., Physiological and behavioral responses to CRF administration; is CRF a mediator of anxiety or stress response?, Brain Res. Rev., 15 (1990) 71-100.
30. [30] Elands, J.P.M., De Kloet, E.R. and De Wied, D., Neurohypophyseal hormone receptors; relation to behavior, Prog. Brain Res., 91 (1992) 459-464.
31. [31] Endröczi, E., Lissák, K., Fekete, T. and De Wied, D., Effects of ACTH on EEG habituation in human subjects, Progr. Brain Res., 32 (1970) 254-262.
32. [32] Fekete, M. and De Wied, D. Facilitation and attenuation of passive avoidance behavior: dose-related effects of the ACTH 4-9 analog ORG 2766. In: E. Endröczi, D. De Wied, L. Angelucci and U. Scapagnini (Eds.), Developments in Neuroscience, Vol. 16, Integrative Neurohumoral Mechanisms, Elsevier Biomedical Press, Amsterdam, 1983, pp. 99-106.
33. [33] Fekete, M., Szipöcs, I., Halmai, L., Franczia, P., Kardos, A., Csonka, E., Szånto-Fekete, M. and Telegdy, G., Cholecystokinin and the central nervous system, Front. Horm. Res., 15 (1987) 175-251.
34. [34] Flood, J.F. and Morley, J.E., Dissociation of the effects of neuropeptide Y on feeding and memory; evidence for pre- and postsynaptic mediation, Peptides, 10 (1989) 963-966.
35. [35] Flood, J.F., Baker, M.L., Hernandez, E.N. and Morley, J.E., Modulation of memory processing by neuropeptide Y varies with brain injection site, Brain Res., 503 (1989) 73-82.
36. [36] Flood, J.F., Baker, M.L., Hernandez, E.N. and Morley, J.E., Modulation of memory retention by neuropeptide K, Brain Res., 520 (1990) 284-290.
37. [37] Flood, J.F., Garland, J.S., Morley, J.E., Vasoactive intestinal peptide (VIP); an amnestic neuropeptide, Peptides, 11 (1990) 933-938.
38. [38] Flood, J.F., Garland, J.S., Morley, J.E., Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala, Brain Res., 585 (1992) 94-104.
39. [39] Gaffori, O., Stewart, J.M. and De Wied, D., Influence of substance P and fragments on passive avoidance behavior, Experientia, 40 (1984) 89-91.
40. [40] Gaillard, A.W.K. and Sanders, A.F., Some effects of ACTH 4-10 on performance during a serial reaction task, Psychopharmacologia, 42 (1975) 201-208.
41. [41] Gaillard, A.W.K. and Varey, C.A., Some effects of an ACTH 4-9 analog (Org 2766) on human performance, Physiol. Behav., 23 (1979) 79-84.
42. [42] Glimcher, P., Margolin, D. and Hoebel, B.G., Rewarding effects of neurotensin in the brain, Ann. New York Acad. Sci., 400 (1982) 422-424.
43. [43] Greven, H.M. and De Wied, D., Structure and behavioural activity of peptides related to corticotrophin and lipotrophin. In: D. de Wied and P.A. van Keep (Eds.), Hormones and the Brain, MTP Press, Lancaster, 1980, pp. 115-127.
44. 8)-vasopressin in five trials with memory-disturbed patients, Hum. Psychopharmacol., 7 (1992) 7-23.
45. [45] Hökfelt, T., Neuropeptides in perspective (the last ten years), Neuron, 7 (1991) 867-879.
46. [46] Huston, J.P. and Staubli, U., Substance P and its effects on learning and memory. In: J.L. Martinez, R.A. Jensen, R.B. Messing, H. Rigter and J.L. McGaugh (Eds.), Endogenous Peptides and Learning and Memory Processes, Academic Press, New York, 1981, pp. 521-540.
47. [47] Joëls, M. and Urban, I., Arginine8-vasopressin enhances the responses of lateral septal neurons in the rat to excitatory amino acids and fimbria-fornix stimuli, Brain Res., 311 (1984) 201-209.
48. [48] Kimura, T., Tanizawa, O., Mori, K., Brownstein, M.J., Okayama, H., Structure and expression of a human oxytocin receptor, Nature, 356 (1992) 526-529.
49. [49] Kovács, G.L. and De Wied, D., Peptidergic modulation of learning and memory processes, Pharmacol. Rev., 46 (1994) 269-291.
50. [50] Kovács, G.L., Veldhuis, H.D., Versteeg, D.H.G. and De Wied, D., Facilitation of avoidance behavior by vasopressin fragments microinjected into limbic midbrain structures, Brain Res., 371 (1986) 17-24.
51. 6]vasopressin-(5-9), but not of vasopressin, Eur. J. Pharmacol., 161 (1989) 27-35.
52. [52] Landgraf, R., Intracerebrally released vasopressin and oxytocin (measurement, mechanisms and behavioural consequences), J. Neuroendocrinol., 7 (1995) 243-253.
53. [53] Liu, B. and Burbach, J.P.H., Nα-acetyl-vasopressin- and Nα-acetyl-oxytocin-like substances; isolation and characterization in the rat neurointermediate pituitary and presence in the brain, J. Neuroendocrinol., 4 (1989) 47-52.
54. [54] Lolait, S.J., O'Carrol, A.M., Mahan, L.C., Felder, C.C., Buton, D.C., Young, W.S., III, Mezey, E. and Browstein, M.J., Extrapituitary expression of the rat V1b receptor gene, Proc. Natl. Acad. Sci. USA, 92 (1995) 6783-6787.
55. [55] Maurice, T., Hiramatsu, M., Kameyama, T., Hasegawa, T. and Nabeshima, T., Cholecystokinin-related peptides, after systemci or central administration, prevent carbon monoxide-induced amnesia in mice, J. Pharmacol. Exp. Ther., 269 (1994) 665-673.
56. [56] Meziane, H., Devigne, C., Tramu, G. and Soumireu-Mourat, B., Effects of anti-CCK-8 antiserum on acquisition and retrieval by mice in an appetitive task, Peptides, 14 (1993) 67-73.
57. 1a arginine vasopressin receptor, Nature, 356 (1992) 523-526.
58. [58] Morley, J.E., Flood, J. and Silver, A.J., Effects of peripheral hormones on memory and ingestive behaviors, Psychoneuroendocrinology, 17 (1992) 391-399.
59. [59] Morley, J.E. and Flood, J.F., Neuropeptide Y and memory processing, Ann. New York Acad. Sci., 611 (1990) 226-231.
60. [60] Mountjoy, K.G., Robbins, L.S., Mortrud, M.T. and Cone, R.D., The cloning of a family of genes that encode the melanocortin receptors, Science, 257 (1992) 1248.
61. [61] Nagel, J.A., Welzl, H., Battog, K. and Huston, J.P., Facilitation of tunnel maze performance by systemic injection of the neurokinin substance P, Peptides, 14 (1993) 85-95.
62. [62] Ogren, S.O., Hökfelt, T., Kask, K., Langel, U. and Bartfai, T., Evidence for a role of the neuropeptide galanin in spatial learning, Neuroscience, 51 (1992) 1-5.
63. [63] Popik, P., Vetulani, J., Bisaga, A. and Van Ree, J.M., Recognition cue in the rat's social memory paradigm, J. Basic Clin. Physiol. Pharmacol., 2 (1991) 315-327.
64. 2-induced retrograde amnesia in rats, Physiol. Behav., 13 (1974) 485-492.
65. [65] Sandman, C.A., George, J., McCanne, T.R., Nolan, J.D., Kaswan, J. and Kastin, A.J., MSH/ACTH 4-10 influences behavioral and physiological measures of attention, J. Clin. Endocrinol. Metab., 44 (1987) 884-891.
66. [66] Stark, H., Burbach, J.P.H., Van der Kleij, A.A.M. and De Wied, D., In vivo conversion of vasopressin after microinjection into limbic brain areas of rats, Peptides, 10 (1989) 717-720.
67. [67] Staubli, U. and Huston, J.P., Facilitation of learning by post-trial injection of substance P into the medial septal nucleus, Behav. Brain Res., 1 (1980) 245-255.
68. [68] Van Wimersma Greidanus, Tj.B., Van Praag, M.C.G., Kalmann, R., Rinkel, G.J.E., Croiset, G., Hoeke. E.C., Van Egmond, M.A.H. and Fekete, M., Behavioral effects of neurotensin, Ann. New York Acad. Sci., 400 (1982) 319-329.
69. [69] Van Wimersma Greidanus, Tj.B., Bohus, B., Kovacs, G.L., Versteeg, D.H.G., Burbach, J.P.H. and De Wied, D., Sites of behavioral and neurochemical action of ACTH-like peptides and neurohypophyseal hormones, Neurosci. Biobehav. Rev., 7 (1983) 453-463.
70. [70] Van Ree, J.M., Memory and neuropeptides. In J.E. Morley and S.G. Korenman (Eds.), Endocrinology and Metabolism in the Elderly, Blackwell Scientific Publications, Boston, 1992, pp. 500-524.
71. [71] Van den Hooff, P., Urban, I.J.A. and De Wied, D. Vasopressin maintains long-term potentiation in rat lateral septum slices, Brain Res., 505 (1989) 181-186.
72. [72] Versteeg, D.H.G., Neurohypophyseal hormones and brain neurochemistry. In: D. De Wied, W.H. Gispen, Tj.B. Van Wimersma Greidanus (Eds.), Neuropeptides and Behavior, Vol. 2., Pergamon Press, Oxford, 1986, pp. 55-83.
73. [73] Wahlestedt, C., Grundemar, L., HÅkanson, R., Heilig, M., Shen, G.H., Zukowska-Groject, Z. and Reis, D.J., Neuropeptide Y receptor subtypes, Y1 and Y2, Ann. New York Acad. Sci., 611 (1990) 7-26.
74. [74] Witter, A., Greven, H.M. and De Wied, D., Correlation between structure behavioral activity and rate of biotransformation of some ACTH 4-9 analogs, J. Pharmacol. Exp. Ther., 193 (1975) 853-860.
75. 1 receptor antagonist, Science, (1991) 572-574.
76. 2 antagonist, Br. J. Pharmacol., (1992) 787-791.